vs
Side-by-side financial comparison of Akebia Therapeutics, Inc. (AKBA) and Day One Biopharmaceuticals, Inc. (DAWN). Click either name above to swap in a different company.
Akebia Therapeutics, Inc. is the larger business by last-quarter revenue ($57.6M vs $39.8M, roughly 1.4× Day One Biopharmaceuticals, Inc.). On growth, Akebia Therapeutics, Inc. posted the faster year-over-year revenue change (23.9% vs -57.6%).
Akebia Therapeutics is a biopharmaceutical company dedicated to developing and commercializing novel therapies for patients with kidney diseases, particularly anemia linked to chronic kidney disease. It operates across global markets, focusing on addressing unmet medical needs in the nephrology care segment.
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing targeted precision oncology therapies for pediatric and young adult patients with genetically driven cancers. It advances novel drug candidates to address unmet medical needs in underserved patient segments, operating primarily in the U.S. and partnering with global oncology research institutions.
AKBA vs DAWN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.6M | $39.8M |
| Net Profit | — | $-19.7M |
| Gross Margin | 78.2% | — |
| Operating Margin | -14.8% | -60.9% |
| Net Margin | — | -49.6% |
| Revenue YoY | 23.9% | -57.6% |
| Net Profit YoY | — | -153.3% |
| EPS (diluted) | $-0.05 | $-0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $57.6M | — | ||
| Q3 25 | $58.8M | $39.8M | ||
| Q2 25 | $62.5M | $33.9M | ||
| Q1 25 | $57.3M | $30.8M | ||
| Q4 24 | $46.5M | — | ||
| Q3 24 | $37.4M | $93.8M | ||
| Q2 24 | $43.6M | — | ||
| Q1 24 | $32.6M | $0 |
| Q4 25 | — | — | ||
| Q3 25 | $540.0K | $-19.7M | ||
| Q2 25 | $247.0K | $-30.3M | ||
| Q1 25 | $6.1M | $-36.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-20.0M | $37.0M | ||
| Q2 24 | $-8.6M | — | ||
| Q1 24 | $-18.0M | $-62.4M |
| Q4 25 | 78.2% | — | ||
| Q3 25 | 84.0% | — | ||
| Q2 25 | 84.1% | — | ||
| Q1 25 | 86.7% | — | ||
| Q4 24 | 56.2% | — | ||
| Q3 24 | 62.2% | — | ||
| Q2 24 | 60.9% | — | ||
| Q1 24 | 64.4% | — |
| Q4 25 | -14.8% | — | ||
| Q3 25 | 7.6% | -60.9% | ||
| Q2 25 | 22.6% | -103.1% | ||
| Q1 25 | 23.6% | -133.5% | ||
| Q4 24 | -30.8% | — | ||
| Q3 24 | -33.4% | 31.6% | ||
| Q2 24 | -20.0% | — | ||
| Q1 24 | -45.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.9% | -49.6% | ||
| Q2 25 | 0.4% | -89.4% | ||
| Q1 25 | 10.7% | -117.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | -53.5% | 39.5% | ||
| Q2 24 | -19.7% | — | ||
| Q1 24 | -55.2% | — |
| Q4 25 | $-0.05 | — | ||
| Q3 25 | $0.00 | $-0.19 | ||
| Q2 25 | $0.00 | $-0.29 | ||
| Q1 25 | $0.03 | $-0.35 | ||
| Q4 24 | $-0.10 | — | ||
| Q3 24 | $-0.10 | $0.38 | ||
| Q2 24 | $-0.04 | — | ||
| Q1 24 | $-0.09 | $-0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $184.8M | $451.6M |
| Total DebtLower is stronger | $48.3M | — |
| Stockholders' EquityBook value | $32.6M | $450.9M |
| Total Assets | $376.6M | $513.8M |
| Debt / EquityLower = less leverage | 1.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $184.8M | — | ||
| Q3 25 | $166.4M | $451.6M | ||
| Q2 25 | $137.3M | $453.1M | ||
| Q1 25 | $113.4M | $473.0M | ||
| Q4 24 | $51.9M | — | ||
| Q3 24 | $34.0M | $558.4M | ||
| Q2 24 | $39.5M | — | ||
| Q1 24 | $42.0M | $317.9M |
| Q4 25 | $48.3M | — | ||
| Q3 25 | $47.6M | — | ||
| Q2 25 | $47.1M | — | ||
| Q1 25 | $46.5M | — | ||
| Q4 24 | $38.7M | — | ||
| Q3 24 | $38.4M | — | ||
| Q2 24 | $38.0M | — | ||
| Q1 24 | $30.1M | — |
| Q4 25 | $32.6M | — | ||
| Q3 25 | $41.6M | $450.9M | ||
| Q2 25 | $29.2M | $460.8M | ||
| Q1 25 | $24.6M | $479.5M | ||
| Q4 24 | $-49.2M | — | ||
| Q3 24 | $-50.4M | $555.5M | ||
| Q2 24 | $-33.8M | — | ||
| Q1 24 | $-27.3M | $296.8M |
| Q4 25 | $376.6M | — | ||
| Q3 25 | $364.2M | $513.8M | ||
| Q2 25 | $345.6M | $519.0M | ||
| Q1 25 | $310.2M | $534.4M | ||
| Q4 24 | $220.7M | — | ||
| Q3 24 | $207.1M | $600.8M | ||
| Q2 24 | $220.2M | — | ||
| Q1 24 | $225.5M | $326.6M |
| Q4 25 | 1.48× | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 1.61× | — | ||
| Q1 25 | 1.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.1M | $-5.8M |
| Free Cash FlowOCF − Capex | $31.1M | — |
| FCF MarginFCF / Revenue | 53.9% | — |
| Capex IntensityCapex / Revenue | 0.1% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $67.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.1M | — | ||
| Q3 25 | $28.1M | $-5.8M | ||
| Q2 25 | $22.3M | $-24.8M | ||
| Q1 25 | $-13.6M | $-59.0M | ||
| Q4 24 | $-4.5M | — | ||
| Q3 24 | $-6.7M | $50.8M | ||
| Q2 24 | $-10.1M | — | ||
| Q1 24 | $-19.4M | $-49.7M |
| Q4 25 | $31.1M | — | ||
| Q3 25 | $28.0M | — | ||
| Q2 25 | $22.2M | $-24.8M | ||
| Q1 25 | $-13.6M | $-59.3M | ||
| Q4 24 | $-4.5M | — | ||
| Q3 24 | $-6.7M | $50.0M | ||
| Q2 24 | $-10.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | 53.9% | — | ||
| Q3 25 | 47.7% | — | ||
| Q2 25 | 35.6% | -73.2% | ||
| Q1 25 | -23.7% | -192.8% | ||
| Q4 24 | -9.6% | — | ||
| Q3 24 | -17.9% | 53.4% | ||
| Q2 24 | -23.1% | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.1% | 0.0% | ||
| Q2 25 | 0.2% | 0.0% | ||
| Q1 25 | 0.0% | 1.0% | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | 0.8% | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | 52.05× | — | ||
| Q2 25 | 90.47× | — | ||
| Q1 25 | -2.22× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.37× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AKBA
| Auryxia | $48.1M | 84% |
| Vafseo | $6.2M | 11% |
| License Collaboration And Other Revenue | $3.3M | 6% |
DAWN
| Products | $38.5M | 97% |
| License Agreement With Ipsen Pharma Sas | $1.3M | 3% |
